Phase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection

BACKGROUND: The development and spread of drug resistant Plasmodium falciparum strains is a major concern and novel anti-malarial drugs are, therefore, needed. Ferroquine is a ferrocenic derivative of chloroquine with proven anti-malarial activity against chloroquine-resistant and -sensitive P. falc...

Descripción completa

Detalles Bibliográficos
Autores principales: Mombo-Ngoma, Ghyslain, Supan, Christian, Dal-Bianco, Matthias P, Missinou, Michel A, Matsiegui, Pierre-Blaise, Ospina Salazar, Carmen L, Issifou, Saadou, Ter-Minassian, Daniel, Ramharter, Michael, Kombila, Maryvonne, Kremsner, Peter G, Lell, Bertrand
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056844/
https://www.ncbi.nlm.nih.gov/pubmed/21362162
http://dx.doi.org/10.1186/1475-2875-10-53

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056844/
https://www.ncbi.nlm.nih.gov/pubmed/21362162
http://dx.doi.org/10.1186/1475-2875-10-53

Ejemplares similares